US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AI Healthcare

650.33

-30.2064-4.44%

Number of Gainers:- -

Number of Losers:4

Number of Flat:- -

PE:- -

High:680.03

Open:680.03

Low:649.89

Close:680.54

Volume:24.85M

Turnover:594.41M

Market Cap:20.61B

Float Cap:16.01B

Loading ...

Cathie Wood’s ARK Investment buys 271K shares of Beam Therapeutics today

Tempus AI awarded up to $9.5M from ARPA-H for autonomous AI in cardiology

Tempus AI Wins up to $9.5 Million ARPA-H Advocate Award for Autonomous Heart Failure Agent

Tempus Secures up to $9.5 Million in Arpa-H Advocate Funding to Deploy First Autonomous AI in Cardiology

THOMSON REUTERS

Tempus AI Initiated at Neutral by UBS

UBS Initiates Coverage on Tempus AI With Neutral Rating, $70 Price Target

MT Newswires Live

JonesTrading Remains a Buy on Beam Therapeutics (BEAM)

Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty Pharma (RPRX)

Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints

Beam Therapeutics falls -12.7%

Tempus AI Price Target Announced at $67.00/Share by Roth Capital

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Rothschild & Co Redburn Initiates Tempus AI at Neutral With $67 Price Target

MT Newswires Live

Beam Therapeutics’ BEAM-302 shows efficacy in Phase 1/2 AATD trial

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of Beam-302 in Alpha-1 Antitrypsin Deficiency (Aatd) at the European Respiratory Society (Ers) Congress 2026

THOMSON REUTERS

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

Tempus AI CEO Lefkofsky to Speak at Morgan Stanley Global Healthcare Conference

The Cancer Vaccine Gold Rush Has Begun. so Has the Race for Picks and Shovels - Heard on the Street

Tempus AI Director David R. Epstein Sells 250 Shares Worth $16,387.50

CRISPR Therapeutics (CRSP) Extends CTX310 Durability, Is The Stock Still Cheap?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/BK4611/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":650.33044,"timestamp":1788983999999,"preClose":680.5368,"halted":0,"volume":24847878,"delay":0,"changeRate":-0.044386,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-30.20636,"latestTime":"09-09 16:00:00 EDT","open":680.0314,"high":680.0314,"low":649.8853,"amount":594413797.571167,"amplitude":0.044297,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789047000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.132513,"peRate":-16.341172,"turnoverRate":0.030225,"increases":0,"decrements":4,"flats":0,"marketCap":20614272384,"floatMarketCap":16012323840},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":680.0314,"amplitude":0.044297,"preClose":680.5368,"low":649.8853,"pbRate":"5.132513","latestPrice":650.33044,"volume":24847878,"delay":0,"open":680.0314,"prevYearClose":658.3995,"prevWeekClose":700.621,"prevMonthClose":691.9381,"prevQuarterClose":681.0329,"fiveDayClose":684.6236,"twentyDayClose":634.3247,"sixtyDayClose":586.231,"secType":"PLATE","market":"US","turnoverRate":0.030225,"peRate":-16.341172,"marketCap":20614272384,"floatMarketCap":16012323840,"timestamp":1788983999999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":0,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666555446","title":"Cathie Wood’s ARK Investment buys 271K shares of Beam Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555446","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666555446?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:10","pubTimestamp":1788999015,"startTime":"0","endTime":"0","summary":"20:05 EDT Cathie Wood’s ARK Investment buys 271K shares of Beam Therapeutics (BEAM) today Published first on TheFly – the ultimate source for real-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-271k-shares-of-beam-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-271k-shares-of-beam-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4539","LU1861559042.SGD","ARKG","SARK","ARKK","BK4505","BK4556","BK4535","ARKF","ARKX","LENZ","BK4611","BK4544","BK4007","BK4585","ARKQ","LU1861558580.USD","BEAM","ARKW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666530872","title":"Tempus AI awarded up to $9.5M from ARPA-H for autonomous AI in cardiology","url":"https://stock-news.laohu8.com/highlight/detail?id=2666530872","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666530872?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:05","pubTimestamp":1788984341,"startTime":"0","endTime":"0","summary":"Tempus AI (TEM) announced that it has been selected by the Advanced Research Projects Agency for Health, an agency within the U.S. Department of He...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-awarded-up-to-9-5m-from-arpa-h-for-autonomous-ai-in-cardiology-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-awarded-up-to-9-5m-from-arpa-h-for-autonomous-ai-in-cardiology-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TEMT","BK4613","TEM","HEAL","BK4121","LU1861558580.USD","ARKG","LU1861559042.SGD","BK4611","TEMC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666371155","title":"Tempus AI Wins up to $9.5 Million ARPA-H Advocate Award for Autonomous Heart Failure Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2666371155","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666371155?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:01","pubTimestamp":1788984085,"startTime":"0","endTime":"0","summary":"Tempus AI wins up to $9.5 million ARPA-H ADVOCATE award for autonomous heart failure agentTempus AI won up to USD 9.5 million from the US Department of Health and Human Services’ ARPA-H ADVOCATE progr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL94GQX6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","ARKG","BK4613","LU1861558580.USD","LU1861559042.SGD","TEM","TEMC","BK4121","TEMT","HEAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666164537","title":"Tempus Secures up to $9.5 Million in Arpa-H Advocate Funding to Deploy First Autonomous AI in Cardiology","url":"https://stock-news.laohu8.com/highlight/detail?id=2666164537","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666164537?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:01","pubTimestamp":1788984074,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN4510GH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TEMC","ARKG","HEAL","BK4613","BK4121","TEMT","TEM","LU1861559042.SGD","BK4611","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666536365","title":"Tempus AI Initiated at Neutral by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2666536365","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666536365?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:35","pubTimestamp":1788960900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TEM/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEMT","BK4613","LU1861559042.SGD","BK4121","HEAL","TEMC","TEM","LU1861558580.USD","BK4611","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666382905","title":"UBS Initiates Coverage on Tempus AI With Neutral Rating, $70 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2666382905","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666382905?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:17","pubTimestamp":1788956270,"startTime":"0","endTime":"0","summary":"Tempus AI (TEM) has an average rating of overweight and mean price target of $66.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HEAL","BK4121","BK4613","LU1861559042.SGD","ARKG","TEMT","TEM","LU1861558580.USD","BK4611","TEMC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666747538","title":"JonesTrading Remains a Buy on Beam Therapeutics (BEAM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666747538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666747538?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:15","pubTimestamp":1788956156,"startTime":"0","endTime":"0","summary":"In a report released today, Boris Peaker from JonesTrading reiterated a Buy rating on Beam Therapeutics, with a price target of $35.00. According t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-remains-a-buy-on-beam-therapeutics-beam-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-remains-a-buy-on-beam-therapeutics-beam-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4535","LU1861558580.USD","BK4588","BK4585","BEAM","LU1861559042.SGD","BK4556","BK4611","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666630973","title":"Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty Pharma (RPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666630973","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666630973?lang=en_us&edition=fundamental","pubTime":"2026-09-09 10:30","pubTimestamp":1788921013,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-amgen-amgn-beam-therapeutics-beam-and-royalty-pharma-rprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-amgen-amgn-beam-therapeutics-beam-and-royalty-pharma-rprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU2112291526.USD","LU0029874061.USD","LU1861559042.SGD","IE0002141913.USD","BEAM","BIB","RPRX","PJP","BK4611","LABU","LU0868494617.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","TBXU","BK4588","BK4535","XLV","BK4534","LU1861558580.USD","BK4599","LU2242646821.SGD","IBBQ","LU2468319806.SGD","LU2242652126.USD","IBB","XBI","PBE","HCSG","IE00B4R5TH58.HKD","BK4566","LU1983299246.USD","SG9999001440.SGD","BK4137","BBH","LU1061106388.HKD","LU1057294990.SGD","IE00BJJMRZ35.SGD","BK4007","LU0320765992.SGD","BK4139","IE0009355771.USD","BK4505","LU0889565916.HKD","LU0289739699.SGD","AMGN","LU0109394709.USD","IHE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372629","title":"Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372629","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372629?lang=en_us&edition=fundamental","pubTime":"2026-09-09 03:24","pubTimestamp":1788895440,"startTime":"0","endTime":"0","summary":"Beam Therapeutics shares were down after the company shared updated data for its trial of a treatment for the genetic condition alpha-1 antitrypsin deficiency.Shares declined 9% to $26.88 on Tuesday. The stock is roughly flat this year.In a Phase 1/2 trial evaluating BEAM-302 for AATD, the treatment was well tolerated with an acceptable safety profile, the company said.The updated results were not worse than previous data, but were not numerically better, either, Evercore ISI analysts led by Cory Kasimov said.At the 12-month mark, total alpha-1 antitrypsin in treated patients came down to 13.5 uM  to 14.4 uM, compared with 16.1 uM at the nine-month mark. The treatment is supposed to increase alpha-1 antitrypsin, a protein made by the liver.About 41% of patients experienced adverse events, with the most common being mild-to-moderate infusion-related reactions.Based on the feedback from the Food and Drug Administration, Beam plans to pursue an accelerated approval pathway for the treatme","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4611","BK4505","BEAM","BK4556","LENZ","BK4535","BK4585","BK4588","BK4539","LU1861559042.SGD","LU1861558580.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665376646","title":"Beam Therapeutics falls -12.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665376646","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665376646?lang=en_us&edition=fundamental","pubTime":"2026-09-08 22:06","pubTimestamp":1788876363,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) is down -12.7%, or -$3.78 to $25.88. Published first on TheFly – the ultimate source for real-time, market-moving breaking...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-falls-12-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-falls-12-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BEAM","BK4535","BK4007","LU1861559042.SGD","BK4585","BK4588","BK4505","BK4539","LU1861558580.USD","BK4139","LENZ","BK4556","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378451","title":"Tempus AI Price Target Announced at $67.00/Share by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378451","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378451?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:34","pubTimestamp":1788870840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TEM/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","TEMC","TEM","BK4613","BK4121","ARKG","LU1861559042.SGD","BK4611","HEAL","TEMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378198","title":"CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378198","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378198?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:30","pubTimestamp":1788870600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, Sept.  08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th A","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357662/0/en/crispr-therapeutics-to-present-at-the-morgan-stanley-24th-annual-global-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","LU1861559042.SGD","BK4137","ARKG","SYNB","BK4139","BK4588","XLV","BK4556","BK4581","LU0128526141.USD","BK4585","CRSP","LU0029874061.USD","HCSG","LU1861558580.USD","LABU","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321422","title":"Rothschild & Co Redburn Initiates Tempus AI at Neutral With $67 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321422","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321422?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:12","pubTimestamp":1788862369,"startTime":"0","endTime":"0","summary":"Tempus AI (TEM) has an average rating of overweight and mean price target of $66.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARKG","HEAL","TEM","TEMT","BK4121","LU1861559042.SGD","BK4611","BK4613","LU1861558580.USD","TEMC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665775321","title":"Beam Therapeutics’ BEAM-302 shows efficacy in Phase 1/2 AATD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665775321","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665775321?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:10","pubTimestamp":1788862245,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) announced updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency, or AATD. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-beam-302-shows-efficacy-in-phase-1-2-aatd-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-beam-302-shows-efficacy-in-phase-1-2-aatd-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","LENZ","BK4556","LU1861559042.SGD","BK4139","BK4611","BEAM","BK4588","LU1861558580.USD","BK4007","BK4585","BK4539","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665290223","title":"Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of Beam-302 in Alpha-1 Antitrypsin Deficiency (Aatd) at the European Respiratory Society (Ers) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665290223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665290223?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA4DNXZ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4588","BK4139","LU1861559042.SGD","BEAM","BK4611","BK4556","LU1861558580.USD","BK4585","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665432460","title":"Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665432460","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665432460?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":"BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Fo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357432/0/en/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-alpha-1-antitrypsin-deficiency-aatd-at-the-european-respiratory-society-ers-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM","BK4139","LU1861559042.SGD","BK4588","EPV","LENZ","ALT","BK4505","BK4556","BK4585","IDNA","BK4535","PRTO","BK4539","BK4599","LU1861558580.USD","BK4611","BK4007","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664334854","title":"Tempus AI CEO Lefkofsky to Speak at Morgan Stanley Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664334854","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664334854?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:30","pubTimestamp":1788525028,"startTime":"0","endTime":"0","summary":"Tempus AI CEO Lefkofsky to speak at Morgan Stanley Global Healthcare ConferenceTempus AI CEO Eric Lefkofsky will join a fireside chat at Morgan Stanley’s 24th Annual Global Healthcare Conference on Se","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL5LrmbK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARKG","LU1861559042.SGD","BK4121","HEAL","LU1861558580.USD","TEMT","TEM","BK4611","BK4613","TEMC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664333870","title":"The Cancer Vaccine Gold Rush Has Begun. so Has the Race for Picks and Shovels - Heard on the Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2664333870","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664333870?lang=en_us&edition=fundamental","pubTime":"2026-09-04 17:30","pubTimestamp":1788514200,"startTime":"0","endTime":"0","summary":"The excitement surrounding Moderna and Merck's personalized mRNA cancer vaccine added more than $50 billion in combined market value for the two drug companies. But it is also creating a gold rush in ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4613","BK4611","LU1861559042.SGD","TEMC","ARKG","TEM","LU1861558580.USD","HEAL","PSNL","TEMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664809740","title":"Tempus AI Director David R. Epstein Sells 250 Shares Worth $16,387.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2664809740","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664809740?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:06","pubTimestamp":1788465961,"startTime":"0","endTime":"0","summary":"Tempus AI director David R. Epstein sells 250 shares worth $16,387.50Tempus AI director David R. Epstein sold 250 shares of Class A common stock on Sept. 1, 2026 at USD 65.55.He held 30,844 shares fol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL1WGVhM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Tempus AI Director David R. Epstein Sells 250 Shares Worth $16,387.50","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","BK4613","BK4121","HEAL","TEMC","TEM","LU1861558580.USD","ARKG","TEMT","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664826961","title":"CRISPR Therapeutics (CRSP) Extends CTX310 Durability, Is The Stock Still Cheap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2664826961","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664826961?lang=en_us&edition=fundamental","pubTime":"2026-09-03 10:26","pubTimestamp":1788402388,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics (CRSP) is back in focus after new Phase 1a durability data for CTX310, its in vivo ANGPTL3 gene editing therapy, highlighted sustained lipid reductions one year after a single infusion.\nAt a share price of $56.92, CRISPR Therapeutics has had a mixed year, with a 30 day share price return of 14.83% and a year to date share price return of 5.86%, while the 1 year total shareholder return of 7.44% suggests that momentum has been improving recently as investors react to the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-extends-ctx310-durability-is-the-st","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-extends-ctx310-durability-is-the-st","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861559042.SGD","ARKG","SYNB","BK4139","SPHQ","BK4588","BK4556","BK4585","CRSP","LU1861558580.USD","DCF","BK4611"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}]}}